Powered by

-Basilea starts phase 1/2 Study FIDES-03 with derazantinib in patients with gastric cancer

Sep 29, 2020 - ENP Newswire

Basel - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has initiated the phase 1/2 study, FIDES-03, with the FGFR inhibitor derazantinib.

The multi-cohort study is evaluating derazantinib in patients with advanced gastric cancer with FGFR genetic aberrations. Derazantinib will be assessed as monotherapy and in combination with other cancer treatments, for instance with Roche's PD-L1 checkpoint inhibitor, atezolizumab.

Basilea will be the sponsor of the study an...